Navigation Links
VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
Date:11/12/2007

SAN FRANCISCO, Nov. 12 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, today announced the expansion of its clinical advisory board. Joining the clinical advisory board's chair, Marc Pfeffer, M.D., Ph.D., Dzau Professor of Medicine, Harvard Medical School, and Senior Physician, Brigham & Women's Hospital in Boston, and Jean-Claude Tardif, M.D., Associate Professor of Medicine, University of Montreal, and Director of Research, Montreal Heart Institute, are Marcelo Di Carli, M.D., Associate Professor of Radiology, and Chief of Nuclear Medicine, Brigham and Women's Hospital; Robert Fenichel, M.D., Ph.D, Former Deputy Division Director, Division of CardioRenal Drug Products, Food and Drug Administration; Peter Libby, M.D., Mallinckrodt Professor of Medicine, and Chief, Cardiovascular Division, Brigham and Women's Hospital; and, Jean-Lucien Rouleau, M.D., Dean, Faculty of Medicine, University of Montreal.

"The addition of these well-respected physicians to VIA's clinical advisory board comes at an important time in our history," said Larry Cohen, Ph.D., president and chief executive officer of VIA. "As we prepare for the release of Phase II clinical trial data in the middle of 2008, our clinical advisory board will provide independent medical, scientific, and regulatory guidance in supporting our efforts to advance VIA-2291 as a treatment of cardiovascular disease."

About VIA-2291

VIA's lead product candidate, VIA-2291, is a small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. VIA-2291 is a potent, selective and reversib
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014  Having the right people at the ... accelerating business growth and achieving clinical and operational goals. ... Leadership Summit, July 20-22, 2014, in San ... executives and healthcare experts discussing how partnerships have positively ... President & Chief Executive Officer of Cape Regional Medical ...
(Date:7/23/2014)... DES MOINES, Iowa (PRWEB) July 23, 2014 ... will join the business as vice president of Agricultural ... from Mendel Biotechnology where he served most recently as ... brings extensive biotechnology and business leadership in the seed ... DuPont Pioneer,” said Paul E. Schickler , president ...
(Date:7/23/2014)... 23, 2014  GrowBLOX Sciences, Inc. (OTCQB: GBLX), a medical ... filing for two medical marijuana dispensary locations in ... to the Clark County, Nevada dispensary ... as previously announced.  GrowBLOX Sciences, CEO Craig ... new applications for dispensaries in the City of ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 OncLive® ... Cancer Center has joined its Strategic Alliance Partnership ... Alliance Partnership program, UNC Lineberger will have the ... raise awareness of its cutting-edge research initiatives, community-directed ... UNC Lineberger will work with OncLive to educate ...
Breaking Biology Technology:MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3
... Repligen Corporation (Nasdaq: RGEN ) announced today that it will ... Wednesday, June 9th, 2010 , before the market opens.  The Company President ... conference call and webcast on the same day at 10:00 a.m. EDT ... Company. , , , ...
... June 2 /PRNewswire-Asia-FirstCall/ -- Huiheng Medical,Inc. ("Huiheng" or the ... an agreement to acquire all of the existing and,outstanding shares of ... consisting of the rights to develop,manufacture and market the ClearPath (TM) ... , , ...
... 2 DATATRAK International, Inc. (OTCQX: DATA), a technology and services ... announced its attendance at the Drug Information Association,s 46th Annual Meeting, ... Washington DC June 13-17 . , ... DATATRAK will be exhibiting at Booth #2435 during ...
Cached Biology Technology:Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results 2Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results 3Huiheng Medical, Inc. Announces Agreement to Acquire the ClearPath (TM) Breast Brachytherapy System 2Huiheng Medical, Inc. Announces Agreement to Acquire the ClearPath (TM) Breast Brachytherapy System 3Huiheng Medical, Inc. Announces Agreement to Acquire the ClearPath (TM) Breast Brachytherapy System 4Huiheng Medical, Inc. Announces Agreement to Acquire the ClearPath (TM) Breast Brachytherapy System 5DATATRAK Exhibiting at the DIA's 46th Annual Meeting 2DATATRAK Exhibiting at the DIA's 46th Annual Meeting 3
(Date:7/23/2014)... world by 2050, according to one of the scenarios ... may be advantageous to the physiology and the biochemical ... plants such as Stylosanthes capitata Vogel , a ... as Brazil., The conclusion is from a study carried ... the Ribeiro Preto Faculty of Philosophy, Sciences and Languages ...
(Date:7/23/2014)... 2014 BCC Research ... GLOBAL MARKETS AND TECHNOLOGIES FOR SENSORS , the global ... grow to nearly $154.4 billion by 2020, with a ... image, flow, and level sensors segment is moving at ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Sensors have become indispensable ...
(Date:7/23/2014)... such as tapeworms, hookworms and a protist called Blastocystis ... new paper that argues we should rethink our views of ... the point, paper co-author Julius Luke even ingested three developmental ... latum . After more than a year with the tapeworms, ... metres each by now, he says he feels fine. , ...
Breaking Biology News(10 mins):An increase in temperature by 2050 may be advantageous to the growth of forage plants 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 4Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 2Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 3Intestinal parasites are 'old friends,' researchers argue 2Intestinal parasites are 'old friends,' researchers argue 3
... release is available in Spanish . , ... at fending off the aging process, known as senescence. To ... plant physiologist Cai-Zhong Jiang is investigating the gene-controlled mechanisms of ... modify flowers, aging-linked genes, or the proteins that are products ...
... Motor Neurone Disease Association is funding its first ever ... of this fatal, neurological condition. Pulling together ... and Prof Sir Ian Wilmut from the University of ... Prof Tom Maniatis of Columbia University New York; the ...
... North American small-mammal communities is so out of whack from ... that the current climate change could push them past a ... say Stanford biologists. The evidence lies in fossils spanning the ... in Northern California. What they found is that although ...
Cached Biology News:What genes help blossoms last longer? 2Harnessing the power of stem cells to unlock the secrets of motor neuron disease 2Harnessing the power of stem cells to unlock the secrets of motor neuron disease 3Harnessing the power of stem cells to unlock the secrets of motor neuron disease 4Small mammals -- and rest of food chain -- at greater risk from global warming than thought 2Small mammals -- and rest of food chain -- at greater risk from global warming than thought 3
... dotLab System brings together two mature, ... immobilized capture surfaces. This combination produces ... for the detection of molecular binding ... labels. , Protein-specific capture molecules are ...
... polymers) are prepared by ... the enzyme, polynucleotide phosphorylase, ... the appropriate, ribonucleoside diphosphate ... exception of catalog number ...
... provides a comprehensive experiment based analysis package ... menus yet sophisticated and powerful functionality., Image ... CCD cameras for easy image capture. ... Digital Video Playback Saturation Warning ...
...
Biology Products: